Genetic Polymorphisms and Statin-Associated Side Effects: The Role of SLCO1B1 and Additional Risk Factors

Read full text Summarise with VIRAT
Authors: Romana Marušić, Tatjana Bačun, Dunja Šojat, Saška Marczi
Cited by: 0
References: 52

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Statins are first-line agents for managing dyslipidemia, primarily prescribed to reduce low-density lipoprotein cholesterol (LDL-C) and prevent atherosclerotic cardiovascular disease (ASCVD). Despite their proven efficacy, there is significant interindividual variability in statin response, with some patients experiencing adverse events such as statin-associated muscle symptoms (SAMS) and hepatotoxicity. These effects are partly attributable to genetic polymorphisms, particularly in the SLCO1B1 gene, which encodes the organic anion-transporting polypeptide 1B1 (OATP1B1) responsible for hepatic statin uptake. The SLCO1B1 rs4149056 polymorphism is associated with impaired transporter function, leading to elevated statin plasma concentrations and a higher risk of statin-induced myopathy, especially with simvastatin. Non-genetic factors, such as hypothyroidism, can exacerbate statin intolerance by impairing lipid metabolism and increasing the risk of myopathy and rhabdomyolysis due to reduced hepatic statin clearance. Vitamin D deficiency has also been linked to increased susceptibility to SAMS, as vitamin D plays a role in muscle function and statin metabolism through CYP enzyme modulation. Coenzyme Q10 (CoQ10) depletion, a consequence of statin therapy due to inhibition of the mevalonate pathway, may further contribute to mitochondrial dysfunction and muscle injury. Incorporating pharmacogenetic testing and addressing modifiable risk factors such as thyroid dysfunction and vitamin D deficiency may optimize statin therapy, reducing adverse effects while maintaining cardiovascular protection. Keywords: hydroxymethylglutaryl-CoA reductase inhibitors; SLCO1B1 gene; hypercholesterolemia; myopathy, statin-induced; pharmacogenomics

Fields of Study & Subjects

Pharmacogenetics and Drug Metabolism Lipoproteins and Cardiovascular Health Nutrition Genetics and Disease

Publication details

Journal / source
Southeastern European medical journal
Volume
10
Issue
1
Pages
15–29
Publication date
23 March 2026
Language
EN